Furthermore, the boost in Ig avidity after dose 3 in patients treated with anti-TNF was smaller than the boost in avidity after dose 2 in the healthy control group and patients with IBD treated with anti-IL-12/23, highlighting delayed and decreased affinity maturation (Figure 7A). Here, TNF is linked to inflammatory bowel disease.